Melanoma/Skin Cancer News

Combination therapy with nivolumab plus ipilimumab conferred an OS benefit for patients with asymptomatic melanoma brain metastases, according to results of the open-label, phase 2 CheckMate 204 study published in The Lancet Oncology.

Lynn M. Schuchter, MD, FASCO, has been elected ASCO president for the 2023-2024 term.

OCT-guided and temperature-controlled hyperthermic treatment could be a safe, noninvasive alternative to surgical tumor removal in superficial basal cell carcinoma, according to a presentation of preliminary data.

City of Hope announced Wednesday that it has entered a definitive agreement to acquire Cancer Treatment Centers of America.

The FDA approved pembrolizumab as adjuvant therapy for adults and children aged 12 years or older with stage IIB or IIC melanoma after complete resection.

Christian S. Hinrichs, MD, is reluctant to give cancer credit for anything good.

Patient-led surveillance following melanoma surgery was safe and feasible, according to a pilot study.

Tumor gene expression profiles have become standard practice to help guide treatment of several cancer types.

Recent molecular science research may provide important insights as to why chimeric antigen receptor T-cell therapies for solid tumors have failed to achieve results that match those observed in blood cancers.

The FDA granted fast track designation to BNT111 for the treatment of advanced melanoma.